Company
Imugene Ltd
ASX:IMU
Imugene Ltd is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours. The company's unique platform technologies seek to harness the body’s immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Imugene is supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.
224 stories · page 11 of 12
Imugene cashes up ahead of hotly anticipated cancer treatment trials
Imugene Limited has further underscored investor confidence in its HER-Vaxx product with about A$756,000 in new government funding as trials for the cancer therapy approach.
Imugene Limited sharpens profile ahead of cancer therapy trials
Cancer survival rates have increased dramatically in recent decades, thanks in no small part to serious breakthroughs in immunotherapy.
Imugene raises $3M to start gastric cancer clinical trial
Proceeds will be used to initiate the company’s Phase 1b/2 clinical trial for its HER-Vaxx gastric cancer treatment and additional preclinical work on HER-Vaxx drug combinations. Shareholder approval will be sought for the placement p
Imugene on track to start gastric cancer clinical trial in 2H 2015
Contract research organisation Simbec-Orion has been selected to fast track plans and logistics for the upcoming HER-Vaxx gastric cancer human clinical trial.
ASX trades sideways, but this immuno-oncology company is up 9.1%
Australian stocks traded sideways today with the ASX200 putting on just 2.4 points. Find out which immuno-oncology company has empirical research demonstrating promising inhibition of tumour cells by its peptide vaccine.
Imugene Limited Melbourne/Sydney Investor Luncheon Presentation
Imugene Limited Melbourne/Sydney Investor Luncheon Presentation
Imugene therapy targets cancer at Melbourne, Sydney Luncheons
The “new” Imugene is involved in one of the hottest areas of cancer study and appears lightly valued V global peers in Immuno-Oncology...immunotherapy has become one of the most promising areas of study for the treatment of a va
Imugene hits milestones on the road to Her-Vaxx 2015 clinical program
The two milestones move Imugene closer towards starting the clinical program for its Her-Vaxx peptide vaccine in the second half of 2015. HER-Vaxx has the potential to improve upon Roche’s blockbuster Herceptin drug that generated ann